Hyaluronan-coated meta-organic framework loaded with cisplatin and oleanolic acid for synergetic chemotherapy of colorec
- PDF / 814,389 Bytes
- 10 Pages / 584.957 x 782.986 pts Page_size
- 37 Downloads / 176 Views
Hyaluronan-coated meta-organic framework loaded with cisplatin and oleanolic acid for synergetic chemotherapy of colorectal cancer Qin Huang1, En Wang1, Weigang Gu2, Wencong Ma2, Yifeng Zhou2,a) 1
Department of Gastroenterology, Enze Hospital, Taizhou Enze Medical Center (Group), Taizhou, Zhejiang Province 318050, China Department of Gastroenterology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province 310006, China a) Address all correspondence to this author. e-mail: [email protected] 2
Received: 22 July 2019; accepted: 23 September 2019
Effective cancer therapy is usually limited by the off target distribution of chemotherapeutic drugs and multidrug resistance (MDR) of cancer cells. As a result, the development of a drug delivery system (DDS) capable of targeting cancer cells while at the same time delivering two or more chemotherapeutic drugs is believed to be a good solution to this dilemma. Herein, a hyaluronan-coated meta-organic framework nanoparticles (HM) were fabricated as a DDS in our study to deliver cisplatin (PDD) and oleanolic acid (Ola). Positive results were obtained in our study which reveal that the DDS (HM/PDD/Ola) is favorable in colorectal cancer (HCT116) therapy by enhancing targeted apoptosis and reversing MDR. Compared with applying free drugs or mono DDS, the dual loaded HM/PDD/Ola showed synergistic effects and better performance, which might be a future alternative for the chemotherapy of colorectal cancer.
Introduction At present, cancer chemotherapy is still the most widely adopted approach for cancer therapy [1, 2, 3]. However, because of the developed multidrug resistance (MDR) in many cancer types, the administration of a single drug molecule usually fails to effectively control the progress of cancers [4, 5]. To the end, the combined administration of different types of drugs has gradually emerged to be an alternative for better performance in cancer therapy [6, 7]. Previous studies have demonstrated that combination therapy could greatly enhance cytotoxicity and reduce dosage, which significantly reduces the unwanted side effects of anticancer drugs. The basic principle for combination therapy is codelivery of at least two drugs targeting different pathways, which ensures the high cytotoxicity to cancer cells [8, 9]. However, the combination therapy greatly relies on the assistance of drug delivery systems (DDSs) to precisely control the dosage, proportion, and even the sequence of loaded cargos. Considering that most of the currently adopted DDSs are not able to satisfy the first two basic requirements, the introduction of a well-designed DDS is the prerequisite for effective combination therapy [2].
ª Materials Research Society 2020
Over the past decades, the development of a novel DDS suitable for cancer therapy is a research hot spot of pharmaceutical science. Various DDSs based on different materials have been developed to test their feasibility in cancer therapy [10, 11, 12]. In particular, the outstanding mer
Data Loading...
